HEALTH CARE SECTOR

BIOTECHNOLOGY INDUSTRY

Last $4.71 USD

Change Today +0.07 / 1.51%

Volume 360.2K

RIGL On Other Exchanges

Symbol

Exchange

NASDAQ GS

Frankfurt

As of 8:10 PM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

Name (Connections)	Board Relationships	Title	Key Developments
Stephen Sherwin M.D.	168 Relationships	Director, Chairman of Finance Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
Bradford Goodwin	18 Relationships	Director and Chairman of Audit Committee
Hollings Renton III	151 Relationships	Director and Member of Audit Committee

Name (Connections)	Board Relationships	Title
Gary Lyons	37 Relationships	Director, Chairman of Compensation Committee and Member of Finance Committee
Walter Moos Ph.D.	7 Relationships	Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
Peter Ringrose M.A, Ph.D.	74 Relationships	Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee

RIGL Compensation vs. Industry
671.6K 384.7K Chief Executive Officer
426.4K 275.5K Chief Financial Officer
533.1K 339.5K Chief Operating Officer
52 Week Price Performance

RIGL

Industry Average

Name (Connections)	Board Relationships	Title	Key Developments
Walter Moos Ph.D.	7 Relationships	Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee	Rigel Pharmaceuticals, Inc. Announces Senior Management Promotions 06/1/10
Stephen Sherwin M.D.	168 Relationships	Director, Chairman of Finance Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee	Daniel Magilavy Joins Rigel as Vice President of Clinical Research 02/26/08
Peter Ringrose M.A, Ph.D.	74 Relationships	Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee	Rigel Pharmaceuticals Inc. Appoints Bradford S. Goodwin to the Board of Directors and Audit Committee 01/25/07

Name (Connections)	Board Relationships	Title
Walter Moos Ph.D.	7 Relationships	Director, Chairman of Compensation Committee and Member of Finance Committee
Peter Ringrose M.A, Ph.D.	74 Relationships	Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee
Stephen Sherwin M.D.	168 Relationships	Director, Member of Nominating & Corporate Governance Committee and Member of Compensation Committee

RIGL and Competitor Insiders vs. External Board
25% 75% Rigel Pharmaceuticals, Inc.
22% 78% Cell Therapeutics, Inc.

Insiders

External Board Members

Name(Connections)	Board Relationships	Title
James Gower	7 Relationships	Chairman, Chief Executive Officer and Member of Finance Committee
Gary Lyons	37 Relationships	Director, Chairman of Compensation Committee and Member of Finance Committee
Stephen Sherwin M.D.	168 Relationships	Director, Chairman of Finance Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee